Contents
- 1 Citation, commencement and interpretation
- 2 Amendments to the Misuse of Drugs Regulations (Northern Ireland) 2002
- 3 Amendments to the Misuse of Drugs Regulations (Northern Ireland) 2002
- 4 Amendments to the Misuse of Drugs Regulations (Northern Ireland) 2002
- 5 Amendments to the Misuse of Drugs Regulations (Northern Ireland) 2002
- 6 Amendments to the Misuse of Drugs Regulations (Northern Ireland) 2002
1Citation, commencement and interpretation#
(1)These Regulations may be cited as the Misuse of Drugs (Amendment) Regulations (Northern Ireland) 2015 and come into operation on 5th March 2015.
(2)The Interpretation Act (Northern Ireland) 1954 shall apply to these Regulations as it applies to an Act of the Northern Ireland Assembly.
2Amendments to the Misuse of Drugs Regulations (Northern Ireland) 2002#
The Misuse of Drugs Regulations (Northern Ireland) 2002 are amended as follows
3Amendments to the Misuse of Drugs Regulations (Northern Ireland) 2002#
In paragraph 1(a) of Schedule 1 (which specifies controlled drugs subject to the requirements of Regulations 14, 15, 16, 18, 19, 20, 23, 26 and 27)—
(a)after “Tenocyclidine” insert—“(6aR,9R-4-acetyl-N, N-diethyl-7-methyl-4, 6, 6a, 7, 8, 9-hexahydroindolo[4, 3-fg]quinoline-9-carboxamide (ALD-52”
(b)after “4-Bromo-2,5-dimethoxy-a-methylphenethylamine” insert—“3,4-dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide (AH-7921)(6aR,9R)-N,N-diethyl-7-allyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide (AL-LAD)(6aR,9R)-N,N-diethyl-7-ethyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide (ETH-LAD)(6aR,9R)-N,N-diethyl-7-propyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide (PRO-LAD)”
(c)after “2-((Dimethylamino)methyl)-1-(3-hydroxyphenyl)cyclohexanol” insert—“2,4-dimethylazetidinyl{(6aR,9R)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3- fg]quinolin-9-yl}methanone (LSZ)”
4Amendments to the Misuse of Drugs Regulations (Northern Ireland) 2002#
For paragraph 1(b) of Schedule 1, substitute—“b any compound (not being a compound for the time being specified in sub-paragraph (a) above) structurally derived from tryptamine or from a ring-hydroxy tryptamine by modification in any of the following ways, that is to say—i by substitution at the nitrogen atom of the side chain to any extent with alkyl or alkenyl substituents, or by inclusion of the nitrogen atom of the side chain (and no other atoms of the side chain) in a cyclic structure;ii by substitution at the carbon atom adjacent to the nitrogen atom of the side chain with alkyl or alkenyl substituents;iii by substitution in the 6-membered ring to any extent with alkyl, alkoxy, haloalkyl, thioalkyl, alkylenedioxy, or halide substituents;iv by substitution at the 2-position of the tryptamine ring system with an alkyl substituent”
Contains public sector information licensed under the Open Government Licence v3.0.